Advanced Renal Cell Carcinoma
Advertisement
First-line IO + IO therapy is linked to higher costs during the first three months of treatment.
Patients were administered oral belzutifan, 120 mg once daily, in addition to oral cabozantinib, 60 mg once daily.
Dr. Albiges discusses the logistical benefits and considerations of subcutaneous administration of nivolumab for RCC.
Dr. Albiges summarizes the CheckMate 67T study, which evaluated the safety and efficacy of subcutaneous nivolumab for RCC.
Dr. Barragán-Carrillo discusses the current state of RCC treatment, including ICIs, TKIs, and dual ICI regimens.
The panelists discuss promising new advancements and novel therapies for treating RCC, including LAG-3 and CAR-T therapies.
The panel discusses how designing effective trials could refine the approach to treatment strategies for RCC.
Part 3 of this roundtable examines adjuvant pembrolizumab and the role of TKIs in treatment sequencing for RCC.
The panelists examine the data on TKIs and immunotherapy for RCC from the TiNivo-2 trial.
Part 1 of this roundtable examines the key differences between the CONTACT-03 and TiNivo-2 trials.
Drs. Beckermann and Barata explore the implications of the negative findings of the CONTACT-03 trial on clinical practice.
In the final part of this roundtable series, the panelists share their thoughts on the most anticipated upcoming trials.
In the fifth segment of this roundtable, the panelists discuss the challenges and barriers of ipi-nivo therapy.
The fourth segment of this roundtable series focuses on the potential benefits of subcutaneous nivolumab versus IV nivolumab.
The third segment of this roundtable focuses on key treatment endpoints when deciding between IO-IO and IO-TKI regimens.
The panel delves into the utility of sarcomatoid features, PD-L1 status, and emerging biomarkers like KIM 1 and ctDNA.
An expert panel debates the latest strategies for optimizing first-line treatment for advanced renal cell carcinoma.
Disease control was achieved in 84.6% of patients, 4.3% reached a complete response, 52% had partial response.
Drs. Karine Tawagi and Christopher Wallis review the SUNNIFORECAST and TiNivo-2 trials at the ESMO Congress 2024.
Better quality of life and higher optimism showed to alter the perception people with metastatic disease have about cure.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.